Visionblue

Trypan Blue


D.o.r.c. Dutch Ophthalmic Research Center (international) B.v.
Human Prescription Drug
NDC 68803-612
Visionblue also known as Trypan Blue is a human prescription drug labeled by 'D.o.r.c. Dutch Ophthalmic Research Center (international) B.v.'. National Drug Code (NDC) number for Visionblue is 68803-612. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Visionblue drug includes Trypan Blue - .3 mg/.5mL . The currest status of Visionblue drug is Active.

Drug Information:

Drug NDC: 68803-612
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Visionblue
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Trypan Blue
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: D.o.r.c. Dutch Ophthalmic Research Center (international) B.v.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:TRYPAN BLUE - .3 mg/.5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAOCULAR
OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 16 Dec, 2004
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 26 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA021670
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:I2ZWO3LS3M
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Diagnostic Dye [EPC]
Dyes [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68803-612-1010 POUCH in 1 CARTON (68803-612-10) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS16 Dec, 2004N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Visionblue trypan blue trypan blue trypan blue free acid sodium phosphate, monobasic, dihydrate sodium phosphate, dibasic, dihydrate sodium chloride water

Indications and Usage:

Visionblue 0.06% - indications & usage section visionblue® 0.06% is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens. highlights of prescribing information these highlights do not include all the information needed to use visionblue® 0.06% safely and effectively. see full prescribing information for visionblue® 0.06%. visionblue® (trypan blue ophthalmic solution) 0.06% initial u.s. approval: 2004 visionblue® 0.06% is an acid di-azo group dye indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.

Warnings and Cautions:

Visionblue 0.06% - warnings and precautions section excessive staining: it is recommended that after injection all excess visionblue® 0.06% is immediately removed from the eye by thorough irrigation of the anterior chamber. excessive staining: excess visionblue® 0.06% should be removed from the eye immediately after staining.

Dosage and Administration:

Visionblue 0.06% - dosage & administration section cataract surgery. visionblue® 0.06% is packaged in a 2.25 ml syringe to which a blunt cannula has to be attached. after opening the eye, an air bubble is injected into the anterior chamber of the eye in order to minimize dilution of visionblue® 0.06% by the aqeous. visionblue® 0.06% is carefully applied onto the anterior lens capsule using a blunt cannula. sufficient staining is achieved as soon as the dye has contacted the capsule. the anterior chamber is then irrigated with balanced salt solution to remove all excess dye. an anterior capsulotomy can then be performed. inject an air bubble into the anterior chamber; carefully apply visionblue® 0.06% onto the lens capsule; remove all excess dye from the anterior chamber.

Dosage Forms and Strength:

Visionblue 0.06% - dosage forms & strengths section visionblue® 0.06% is supplied in 2.25 ml syringes filled to a volume of 0.5 ml. visionblue® (trypan blue ophthalmic solution) 0.06% in a volume of 0.5 ml.

Contraindications:

Visionblue 0.06% - contraindications section visionblue® 0.06% is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (iol) is planned to be inserted into the eye. the dye may be absorbed by the iol and stain it. insertion of a non-hydrated (dry-state), hydrophilic acrylic intraocular lens (iol).

Adverse Reactions:

Visionblue 0.06% - adverse reactions section adverse reactions reported following use of visionblue® 0.06% include discoloration of high water content hydrogen intraocular lenses (see contraindications) and inadvertent staining of the posterior lens capsule and vitreous face. staining of the posterior lens capsule or staining of the vitreous face is generally self limited, lasting up to one week. inadvertent staining of the posterior lens capsule and vitreous face. to report suspected adverse reactions contact fda at 1-800-fda-1088 or www.fda.gov/medwatch

Use in Specific Population:

Visionblue 0.06% - use in specific populations section trypan blue should not be given to pregnant women. visionblue 0.06% - pregnancy section teratogenic effects: pregnancy category c. trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. the majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. the teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. these doses are approximately 10,000- and 5,000-fold the maximum recommended human dose of 0.3 mg per injection based in a 60 kg person, assuming that the whole dose is completely absorbed. characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. trypan blue also caused an increase in post-implantation mortality, and decreased fetal weight. in the monkey, trypan blue caused abortions with single or two daily doses of 50 mg/kg between 20th to
25th days of pregnancy, but no apparent increase in birth defects (approximately 10,000-fold the maximum recommended human daily dose of 0.3 mg per injection, assuming total absorption). there are no adequate and well-controlled studies in pregnant women. trypan blue should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus. visionblue 0.06% - nursing mothers section it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when trypan blue is administered to a nursing woman. visionblue 0.06% - pediatric use section the safety and effectiveness of trypan blue have been established in pediatric patients. use of trypan blue is supported by evidence from an adequate and well-controlled study in pediatric patients. visionblue 0.06% - geriatric use section no overall differences in safety and effectiveness have been observed between elderly and younger patients.

Use in Pregnancy:

Visionblue 0.06% - pregnancy section teratogenic effects: pregnancy category c. trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. the majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. the teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. these doses are approximately 10,000- and 5,000-fold the maximum recommended human dose of 0.3 mg per injection based in a 60 kg person, assuming that the whole dose is completely absorbed. characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. trypan blue also caused an increase in post-implantation mortality, and decreased fetal weight. in the monkey, trypan blue caused abortions with single or two daily doses of 50 mg/kg between 20th to 25th days of pregnancy, but no apparent increase in birth defects (approximately 10,000-fold the maximum
recommended human daily dose of 0.3 mg per injection, assuming total absorption). there are no adequate and well-controlled studies in pregnant women. trypan blue should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Visionblue 0.06% - pediatric use section the safety and effectiveness of trypan blue have been established in pediatric patients. use of trypan blue is supported by evidence from an adequate and well-controlled study in pediatric patients.

Geriatric Use:

Visionblue 0.06% - geriatric use section no overall differences in safety and effectiveness have been observed between elderly and younger patients.

Description:

Visionblue 0.06% - description section visionblue® (trypan blue ophthalmic solution) 0.06% is a sterile solution of trypan blue (an acid di-azo group dye). visionblue® 0.06% is a selective tissue staining agent for use as a medical aid in ophthalmic surgery. each ml of visionblue® 0.06% contains: 0.6 mg trypan blue; 1.9 mg sodium mono-hydrogen orthophosphate (na 2 hpo 4 ·2h 2 o); 0.3 mg sodium di-hydrogen orthophosphate (nah 2 po 4 ·2h 2 o); 8.2 mg sodium chloride (nacl); and water for injection. the ph is 7.3 – 7.6. the osmolality is 257-314 mosm/kg. the drug substance trypan blue has the chemical name 3,3’-[(3,3’-dimethyl-4,4’-biphenylylene) bis (azo)] bis (5-amino-4-hydroxy-2,7-naphthalenedisulfonic acid) tetra sodium salt, a molecular weight of 960.8, a molecular formula of c 34 h 24 n 6 na 4 o 14 s 4 , and has the following chemical structure: chemical structure visionblue

Clinical Pharmacology:

Visionblue 0.06% - clinical pharmacology section visionblue 0.06% - mechanism of action section visionblue® 0.06% selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens. visionblue® 0.06% is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. excess dye is washed out of the anterior chamber. the dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.

Mechanism of Action:

Visionblue 0.06% - mechanism of action section visionblue® 0.06% selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens. visionblue® 0.06% is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. excess dye is washed out of the anterior chamber. the dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.

Nonclinical Toxicology:

Visionblue 0.06% - nonclinical toxicology section visionblue 0.06% - carcinogenesis & mutagenesis & impairment of fertility section trypan blue is carcinogenic in rats. wistar/lewis rats developed lymphomas after receiving subcutaneous injections of 1% trypan blue dosed at 50 mg/kg every other week for 52 weeks (total does approximately 250,000-fold the maximum recommended human dose of 0.3 mg per injection in a 60 kg person, assuming total absorption). trypan blue was mutagenic in the ames test and caused dna strand breaks in vitro.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Visionblue 0.06% - carcinogenesis & mutagenesis & impairment of fertility section trypan blue is carcinogenic in rats. wistar/lewis rats developed lymphomas after receiving subcutaneous injections of 1% trypan blue dosed at 50 mg/kg every other week for 52 weeks (total does approximately 250,000-fold the maximum recommended human dose of 0.3 mg per injection in a 60 kg person, assuming total absorption). trypan blue was mutagenic in the ames test and caused dna strand breaks in vitro.

How Supplied:

Visionblue 0.06% - how supplied section visionblue® 0.06% is supplied as follows: 0.5 ml of visionblue® 0.06% in a sterile single-use luer lok, 2.25 ml glass syringe, grey rubber plunger stopper and tip cap with polypropylene plunger rod in a peel pouch. ten pouched products are packed in on distribution box.

Package Label Principal Display Panel:

Visionblue 0.06% - package label.principal display panel visionblue 0.06% - box visionblue 0.06% - labels visionblue 0.06% - shipping box label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.